If you ask five electronic data capture (EDC) vendors whether their system is 21 CFR Part 11 compliant, they'll likely all say yes.
But the responsibility for Part 11 compliance is up to the organization that runs the system, and software only makes it achievable, not a guarantee. FDA's guidance on electronic systems, records, and signatures in clinical investigations acknowledges that many EDC providers perform validation on behalf of their customers - but responsibility for the records still sits with the sponsor.
So the better question is how much of the Part 11 work each vendor carries and how much is up to the sponsor's quality team. The five EDCs below are evaluated on three things that separate them: validation burden, audit trail depth, and the split between evidence the vendor supplies and evidence the sponsor has to produce.
What Part 11 expects an EDC to do
Part 11 has three subparts, and the complete 21 CFR Part 11 guide discusses each subpart. For an EDC, a handful of clauses carry most of the weight:
- 11.10(a), validation. The system must be validated for accuracy, reliability, consistent intended performance, and the ability to discern invalid or altered records.
- 11.10(e), audit trails. Secure, computer-generated, time-stamped audit trails must record operator entries and actions, preserve previously recorded values, and be retained as long as the underlying records.
- 11.10(k), documentation controls. Distribution of, access to, and changes to system documentation must be controlled.
- 11.50 and 11.70, signatures. Each signed record must show the signer's printed name, the date and time, and the meaning of the signature, and the signature must be permanently linked to its record.
- 11.100(c), certification. The organization must certify to FDA that its electronic signatures are the legally binding equivalent of handwritten ones.
Some of those clauses describe product features. Others describe things only the sponsor can do. A software vendor isn't going to send FDA a sponsor's 11.100(c) certification letter, write its standard operating procedures (SOPs), or train its study staff under 11.10(i). So if a software vendor says they do it all for you, take it with a grain of salt.
Three criteria that separate Part 11 EDCs
1. Validation burden
Every reputable vendor validates its own platform release. The differences in that validation show up downstream.
A sponsor still has to confirm that its study configuration works as intended: the electronic case report forms (eCRFs), edit checks, randomization, role permissions, and any integrations. Then the sponsor has to assess every new release the vendor ships. A platform that releases quarterly and supplies only a summary certificate creates far more sponsor work than one that releases with a traceability matrix and an impact assessment the sponsor can file directly.
The questions to ask are specific. Will the vendor provide a requirements traceability matrix mapped to Part 11 clauses? Does it include test evidence or only a summary? How often do releases ship, and who assesses their impact on a validated study?
2. Audit trail depth
Part 11 sets specific expectations: who changed what, when, with the old value preserved. It doesn't require a reason for change. ISO 14155 and ICH good clinical practice (GCP) expect justification, however, which means a device sponsor running a study under both frameworks needs reason-for-change capture whether or not Part 11 asks for it.
Depth also means coverage. A thin audit trail logs data entry and stops there. A more sophisticated one also records queries, source data verification flags, signatures, form version changes, and user permission changes. The sponsor should be able to export it in a readable format without opening a support ticket. Inspectors don't always wait for tickets.
3. Vendor-supplied evidence versus sponsor-produced evidence
The split usually looks like this.
| Evidence | Typically vendor | Typically sponsor |
|---|---|---|
| Platform validation report and test evidence | Yes | Reviews and files it |
| Requirements traceability matrix to Part 11 | Varies widely | Builds it if the vendor does not |
| Release notes and impact assessments | Varies widely | Assesses every release |
| Study-level user acceptance testing (UAT) | Rarely | Yes |
| SOPs, training records, 11.100(c) letter | No | Yes |
The rows marked "varies widely" are where EDCs actually differ, and they are where the five platforms below separate.
→ BONUS RESOURCE: Download the 21 CFR Part 11 compliance checklist for clinical records and e-signatures to run this evaluation against any EDC on your shortlist.
The top 5 EDCs for 21 CFR Part 11 compliance
The ranking below orders platforms by how much Part 11 evidence a medical device sponsor receives ready to file, weighed against how much it has to build itself.
1. Greenlight Guru Clinical
Best for: medical device, IVD, and SaMD sponsors who want the validation package handed over rather than assembled.
Greenlight Guru Clinical (formerly SMART-TRIAL) is pre-validated against FDA and ISO 14155 requirements, and Greenlight Guru supplies the system validation documentation to customers. Ready-to-use compliance document templates cover the procedural side, which shortens the distance between signing a contract and having a filed validation record.
Audit trails, Part 11 electronic signatures, and role-based access are built into the platform, with workflows built around ISO 14155 rather than adapted from drug research. Actions taken through the platform's AI assistant pass through user review before they run, and each approved step is written to the audit trail.
Study configuration is no-code. A clinical team can change an eCRF without a vendor ticket, which keeps configuration changes inside the sponsor's own change control rather than waiting on a vendor's queue.
What the sponsor still owns: SOPs, training, the 11.100(c) letter, and UAT on its own eCRFs and edit checks. The platform is built for device studies, so a drug-led program would sit outside its design.
2. Medidata Rave EDC
Best for: large, multi-region programs with an in-house validation team.
Rave is the incumbent in global drug trials. Medidata publishes a regulatory compliance summary that maps the platform to Part 11, and its audit trail captures data provenance, user actions, and change history with exportable reports.
The validation burden sits mostly in configuration. Rave studies tend to be complex builds, and an entire services market exists to produce Rave-specific validation deliverables for sponsors: user requirements, risk assessments, installation, operational, and performance qualification protocols, and traceability matrices. A sponsor buying Rave should budget for that work internally or through a partner.
For device sponsors, the platform was built around drug trial structures. Device adverse event categories, device deficiency reporting, and post-market follow-up generally need configuration, and every configured element is something the sponsor has to verify. The trade-offs are covered in detail in what device studies give up on a pharma EDC.
3. Oracle Clinical One
Best for: sponsors already on Oracle infrastructure with a release management process in place.
Oracle is more explicit than most about where its evidence stops. Each release ships with a Product Verification Pack containing control testing evidence and a traceability matrix. Oracle notes that the matrix is a subset of its master matrix and does not include every test case. Since release 22.4, Oracle has also provided a Part 11 control mapping document that cross-references its tested controls to GxP requirements.
Oracle's documentation is typically very useful. The burden comes from cadence. Clinical One ships frequent releases, and sponsors have hired outside firms specifically to keep their validated state current across quarterly updates. Oracle's own GxP advisory states that customers remain responsible for assessing the platform against their regulatory obligations.
4. OpenClinica Enterprise
Best for: cost-conscious sponsors willing to read the edition fine print.
OpenClinica's commercial offering comes with a compliance support package that includes software requirements specifications and a traceability matrix tying test cases, results, and artifacts to requirements, including Part 11. Each release is validated under OpenClinica's quality system, and the platform builds medical coding into the EDC so coded terms do not leave the system's audit trail.
It also depends on what edition you use. OpenClinica's open-source Community Edition is self-hosted, which means the hosting organization owns infrastructure qualification and the full validation package. A sponsor evaluating "OpenClinica" should confirm which edition a CRO or site is running before assuming any vendor documentation exists.
5. REDCap
Best for: academic-partnered studies, with a significant asterisk.
REDCap belongs on any Part 11 list because device sponsors run into it constantly through academic investigator sites. It is free software distributed through a consortium, and each hosting institution acts as system owner. The institution configures, validates, and maintains its own instance.
The software includes Part 11-oriented features such as electronic signatures on locked forms. Whether a specific instance meets Part 11 depends entirely on the institution. A National Center for Advancing Translational Sciences working group convened in late 2023 published an implementation guide in January 2026 that maps Part 11 sections 11.10 through 11.300 to REDCap features, institutional procedures, and validation evidence. Some institutions run dedicated, validated Part 11 instances and charge for them. Others state that their instance should not be used for Part 11 studies.
If an investigator site proposes REDCap for a sponsored device study, the sponsor should ask which instance will host the data and request that instance's validation package before agreeing. A separately sold commercial cloud version exists with vendor-supplied validation, and it should be evaluated as a different product.
→ BONUS RESOURCE: Use the ISO 14155 compliance checklist to check the GCP side of your EDC decision alongside Part 11.
Side-by-side summary
| EDC | Vendor validation evidence | Main sponsor burden | Built for |
|---|---|---|---|
| Greenlight Guru Clinical | Validation documentation and compliance templates supplied | Study UAT, SOPs, training | Medical devices |
| Medidata Rave EDC | Regulatory compliance summary | Complex configuration validation | Global drug trials |
| Oracle Clinical One | Per-release verification pack, Part 11 control map | Keeping pace with frequent releases | Enterprise sponsors |
| OpenClinica Enterprise | Requirements specs and Part 11 traceability matrix | Edition confirmation, study validation | Pharma and biotech |
| REDCap | Depends on the hosting institution | Potentially the entire validation package | Academic research |
Three requests to send every vendor
A compliance badge is a good starting point. These three requests separate vendors faster than what you're likely to see in a demo.
First, ask for the Part 11 traceability matrix for the current release. Second, ask for a sample audit trail export from a test study that shows a changed value, a query, and a signature, so the depth is visible on paper. Third, ask for the release schedule and the impact assessment from the most recent release.
Speed and completeness matter here. How a vendor answers those three requests predicts the sponsor's future validation workload better than any feature list, and the same logic drives the best QMS software for medical devices comparison for quality system software. For the broader device-specific selection criteria beyond Part 11, see the 10 tips for selecting EDC software for clinical investigations.
Keep reading
If you are building out your Part 11 and EDC evaluation, these related guides go deeper on specific pieces:
- 21 CFR Part 11: a complete guide to the requirements
- Tips for ensuring your clinical data complies with FDA's 21 CFR Part 11
- EDC systems for clinical trials: the definitive guide for device manufacturers
- How to choose an EDC system for medical device clinical investigations
- What you give up when your device study runs on a pharma EDC
- FDA guidance on electronic systems, records, and signatures in clinical investigations
Device sponsors who want Part 11 evidence delivered with the platform can see how Greenlight Guru Clinical handles validation for medical device studies.
Greenlight Guru is the leading cloud-based platform purpose-built for MedTech companies. The end-to-end solution streamlines product development, quality management, and clinical data management by integrating cross-functional teams, processes, and data throughout the entire product lifecycle. Greenlight Guru’s...
Read More Posts
How to choose an EDC system for medical device clinical investigations
What you give up when your device study runs on a pharma EDC
Clinical evidence for first-time study teams: what to get right before subject one
Get your free PDF
PMCF Activity Guide



